TScan is a clinical-stage biotechnology company dedicated to changing lives by developing safe and effective T-cell therapies for patients.
Our approach is based on the premise that conventional T cells provide the most effective way to fight cancer, and that by genetically reprogramming T cells with highly effective, naturally occurring T cell receptors (TCRs), we can harness the power of the human immune system to deliver life-changing therapies to patients.
We are advancing a robust pipeline of TCR-T therapy candidates derived from our proprietary platform to treat patients with heme malignancies and solid tumors
Our proprietary platform is designed to discover anti-cancer TCRs from patients with exceptional responses to immunotherapy.
We are committed to bringing new immunotherapies to cancer patients.
